1ZIK
| |
1ZIM
| |
1ZIL
| |
5C74
| Structure of a novel protein arginine methyltransferase | Descriptor: | NICKEL (II) ION, Protein arginine N-methyltransferase SFM1, SULFATE ION | Authors: | Lv, F, Ding, J. | Deposit date: | 2015-06-24 | Release date: | 2016-01-13 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structural basis for Sfm1 functioning as a protein arginine methyltransferase. Cell Discov, 1, 2015
|
|
7CGW
| Complex structure of PD-1 and tislelizumab Fab | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Heavy chain of tislelizumab Fab, Light chain of tislelizumab Fab, ... | Authors: | Hong, Y, Feng, Y.C, Liu, Y. | Deposit date: | 2020-07-02 | Release date: | 2021-04-07 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (3.2 Å) | Cite: | Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. Febs Open Bio, 11, 2021
|
|
7TEU
| Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1 | Descriptor: | 3-{(4S)-2-[(cyclopropanecarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}-N-{3-[(4-ethylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl}-4-methylbenzamide, GLYCEROL, Tyrosine-protein kinase JAK2 | Authors: | Hubbard, S.R. | Deposit date: | 2022-01-05 | Release date: | 2023-06-21 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (1.45 Å) | Cite: | New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell Chem Biol, 30, 2023
|
|
6JYJ
| Crystal structure of FAM46B (TENT5B) | Descriptor: | CITRATE ANION, Terminal nucleotidyltransferase 5B | Authors: | Zhang, H, Hu, J.L, Gao, S. | Deposit date: | 2019-04-26 | Release date: | 2020-03-04 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.693199 Å) | Cite: | FAM46B is a prokaryotic-like cytoplasmic poly(A) polymerase essential in human embryonic stem cells. Nucleic Acids Res., 48, 2020
|
|
7VRE
| The crystal structure of EGFR T790M/C797S with the inhibitor HCD2892 | Descriptor: | 5-chloranyl-N-[5-chloranyl-2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-(1-ethylsulfonylindol-3-yl)pyrimidin-2-amine, Epidermal growth factor receptor | Authors: | Zhu, S.J. | Deposit date: | 2021-10-22 | Release date: | 2022-06-08 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.507 Å) | Cite: | Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J.Med.Chem., 65, 2022
|
|
7VRA
| The crystal structure of EGFR T790M/C797S with the inhibitor HC5476 | Descriptor: | 25-chloro-11-(ethylsulfonyl)-44-morpholino-11H-5,12-dioxa-3-aza-1(3,6)-indola-2(4,2)-pyrimidina-4(1,3)-benzenacyclododecaphane, Epidermal growth factor receptor | Authors: | Zhu, S.J. | Deposit date: | 2021-10-22 | Release date: | 2022-06-08 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.41 Å) | Cite: | Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J.Med.Chem., 65, 2022
|
|
5TX3
| Structure of Maternal Embryonic Leucine Zipper Kinase | Descriptor: | 7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-2-({3-[(pyrrolidin-1-yl)methyl]phenyl}amino)-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one, Maternal embryonic leucine zipper kinase | Authors: | Li, Q, Seo, H.-S, Huang, H.-T, Gray, N.S, Dhe-Paganon, S, Eck, M.J. | Deposit date: | 2016-11-15 | Release date: | 2017-11-22 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (2.9 Å) | Cite: | MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife, 6, 2017
|
|
5TWY
| Structure of Maternal Embryonic Leucine Zipper Kinase | Descriptor: | 2-(benzyloxy)-4-(1H-pyrazol-4-yl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzamide, Maternal embryonic leucine zipper kinase | Authors: | Seo, H.-S, Dhe-Paganon, S. | Deposit date: | 2016-11-15 | Release date: | 2017-11-22 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (2.91 Å) | Cite: | MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife, 6, 2017
|
|
5TWU
| Structure of Maternal Embryonic Leucine Zipper Kinase | Descriptor: | Maternal embryonic leucine zipper kinase | Authors: | Li, Q, Seo, H.-S, Huang, H.-T, Gray, N.S, Dhe-Paganon, S, Eck, M.J. | Deposit date: | 2016-11-14 | Release date: | 2017-11-22 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (2.603 Å) | Cite: | MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife, 6, 2017
|
|
5TWL
| Structure of Maternal Embryonic Leucine Zipper Kinase | Descriptor: | 9-(3,5-dichloro-4-hydroxyphenyl)-1-{trans-4-[(dimethylamino)methyl]cyclohexyl}-3,4-dihydropyrimido[5,4-c]quinolin-2(1H)-one, Maternal embryonic leucine zipper kinase | Authors: | Seo, H.-S, Huang, H.-T, Gray, N.S, Dhe-Paganon, S. | Deposit date: | 2016-11-14 | Release date: | 2017-11-22 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (2.42 Å) | Cite: | MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife, 6, 2017
|
|
5TWZ
| Structure of Maternal Embryonic Leucine Zipper Kinase | Descriptor: | 7-{[2-methoxy-4-(1H-pyrazol-4-yl)benzoyl]amino}-2,3,4,5-tetrahydro-1H-3-benzazepinium, Maternal embryonic leucine zipper kinase | Authors: | Seo, H.-Y, Dhe-Paganon, S. | Deposit date: | 2016-11-15 | Release date: | 2017-11-22 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (2.631 Å) | Cite: | MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife, 6, 2017
|
|
4GRB
| Casein kinase 2 (CK2) bound to inhibitor | Descriptor: | 5-(2-{[4-(dimethylcarbamoyl)phenyl]amino}-4-methoxypyrimidin-5-yl)thiophene-3-carboxylic acid, CHLORIDE ION, Casein kinase II subunit alpha | Authors: | Larsen, N.A, Dowling, J.E, Ferguson, A.D. | Deposit date: | 2012-08-24 | Release date: | 2013-08-28 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2.15 Å) | Cite: | Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett, 4, 2013
|
|
7DFT
| Crystal structure of Xanthomonas oryzae ClpP | Descriptor: | ATP-dependent Clp protease proteolytic subunit, CHLORIDE ION | Authors: | Yang, C.-G, Yang, T. | Deposit date: | 2020-11-09 | Release date: | 2021-05-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Dysregulation of ClpP by Small-Molecule Activators Used Against Xanthomonas oryzae pv. oryzae Infections. J.Agric.Food Chem., 69, 2021
|
|
7DFU
| |
7DY9
| Thermotoga maritima ferritin mutant-FLAL | Descriptor: | Ferritin | Authors: | Zhao, G, Zhang, X. | Deposit date: | 2021-01-20 | Release date: | 2021-09-01 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.303 Å) | Cite: | Protein interface redesign facilitates the transformation of nanocage building blocks to 1D and 2D nanomaterials. Nat Commun, 12, 2021
|
|
7DY8
| Thermotoga maritima ferritin mutant-FLAL | Descriptor: | CALCIUM ION, FE (III) ION, Ferritin | Authors: | Zhang, X, Zhao, G. | Deposit date: | 2021-01-20 | Release date: | 2021-09-01 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.103 Å) | Cite: | Protein interface redesign facilitates the transformation of nanocage building blocks to 1D and 2D nanomaterials. Nat Commun, 12, 2021
|
|
7DYA
| Crystal structure of TmFtn with calcium ions | Descriptor: | CALCIUM ION, FE (III) ION, Ferritin | Authors: | Zhang, X, Zhao, G. | Deposit date: | 2021-01-20 | Release date: | 2021-09-01 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.197 Å) | Cite: | Protein interface redesign facilitates the transformation of nanocage building blocks to 1D and 2D nanomaterials. Nat Commun, 12, 2021
|
|
7DYB
| Thermotoga maritima ferritin mutant-FLAL-L | Descriptor: | FE (III) ION, Ferritin | Authors: | Zhao, G, Zhang, X. | Deposit date: | 2021-01-20 | Release date: | 2021-09-01 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.779 Å) | Cite: | Protein interface redesign facilitates the transformation of nanocage building blocks to 1D and 2D nanomaterials. Nat Commun, 12, 2021
|
|
5XV7
| SRPK1 in complex with Alectinib | Descriptor: | 1,2-ETHANEDIOL, 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, serine-arginine (SR) protein kinase 1 | Authors: | Zeng, C, Ngo, J.C.K. | Deposit date: | 2017-06-26 | Release date: | 2018-03-14 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (2.32 Å) | Cite: | SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform Cell Chem Biol, 25, 2018
|
|
5YAD
| Crystal structure of Marf1 Lotus domain from Mus musculus | Descriptor: | GLYCEROL, Meiosis regulator and mRNA stability factor 1, SULFATE ION | Authors: | Yao, Q.Q, Wu, B.X, Ma, J.B. | Deposit date: | 2017-08-31 | Release date: | 2018-10-03 | Last modified: | 2018-11-14 | Method: | X-RAY DIFFRACTION (1.76 Å) | Cite: | Ribonuclease activity of MARF1 controls oocyte RNA homeostasis and genome integrity in mice. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
5YAA
| Crystal structure of Marf1 NYN domain from Mus musculus | Descriptor: | GLYCEROL, Meiosis regulator and mRNA stability factor 1 | Authors: | Yao, Q.Q, Wu, B.X, Ma, J.B. | Deposit date: | 2017-08-31 | Release date: | 2018-10-03 | Last modified: | 2018-11-14 | Method: | X-RAY DIFFRACTION (1.75 Å) | Cite: | Ribonuclease activity of MARF1 controls oocyte RNA homeostasis and genome integrity in mice. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
5ZZ2
| Crystal structure of PDE5 in complex with inhibitor LW1634 | Descriptor: | 3-[(2H-1,3-benzodioxol-5-yl)methyl]-8-fluoro-1-(1,3-thiazol-2-yl)[1]benzopyrano[2,3-c]pyrrol-9(2H)-one, MAGNESIUM ION, SULFATE ION, ... | Authors: | Wu, D, Huang, Y.D, Huang, Y.Y, Luo, H.B. | Deposit date: | 2018-05-29 | Release date: | 2018-09-19 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (2.6 Å) | Cite: | Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. J. Med. Chem., 61, 2018
|
|